Last reviewed · How we verify
NCT03500913
Adipose Tissue and Serum Inflammation in GH Deficiency
trial testing Growth Hormone in Growth Hormone Deficiency in 19 participants. Completed in 20 February 2020.
12 February 2020
Quick facts
| Lead sponsor | Columbia University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 19 |
| Start date | 19 May 2019 |
| Primary completion | 12 February 2020 |
| Estimated completion | 20 February 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Growth Hormone — full drug profile →
Conditions studied
- Growth Hormone Deficiency — all drugs for Growth Hormone Deficiency →
Sponsor
Columbia University
Who can join
Adults 18 to 65, any sex, with Growth Hormone Deficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will examine adipose tissue inflammation and adipokine expression and serum markers of inflammation and adipokine levels in patients with growth hormone (GH) deficiency before and after treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03500913
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Growth Hormone
Trials testing the same drug.
- NCT05447208 — Effect of GH on the Blastocyst Euploid Rate in AMA Patients · Phase 3 · recruiting
- NCT05253287 — Growth Hormone in Decompensated Liver Cirrhosis · Phase 2, PHASE3 · completed
- NCT05187377 — A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism · Phase 2 · completed
- NCT05089344 — Growth Hormone Pretreatment in Poseidon Type IV Undergoing ICSI Using Minimal Induction Protocol: A Randomized Controlle · NA · unknown
- NCT04532554 — Growth Hormone in Obese Cases With Covid-19 · Phase 4 · withdrawn
Other recruiting trials for Growth Hormone Deficiency
Currently open trials in the same condition.
- NCT06542809 — Evaluation of the Propensity of Patients Under rhGH to Envision a Modification of Their Treatment Regimen Toward LAGH · NA · recruiting
- NCT05681299 — Effects of GH and Lirglutide on AgRP · Phase 4 · recruiting
- NCT06455956 — Use of miRNAs in Growth Hormone Deficiency (GHD) · recruiting
Other Columbia University trials
Trials by the same sponsor.
- NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · not yet recruiting
- NCT07264582 — HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking · NA · not yet recruiting
- NCT05992415 — Know Your Pressures NYC · NA · not yet recruiting
- NCT05645211 — The AgRP and GH/IGF-1 Axis in Children · not yet recruiting
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03500913 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Columbia University
- Last refreshed: 13 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03500913.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing